Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Saturday, June 22, 2024 | Back issues
Courthouse News Service Courthouse News Service

Investment Strategies

MANHATTAN - An endocrinologist is still awaiting share certificates after investing half a million dollars in Medolife based on its Escozine cancer treatment, derived from the venom of blue scorpions, and its "polarization technology," she claims in a federal complaint.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.